Fig. 6

ERp44 facilitated chemoresistance in vivo. A. The first four groups represented that CNE2 cells transfected with shERp44 or NC were subcutaneously injected into the mice. After tumor formation, cisplatin was intraperitoneal injected every 2 days. The last two groups represented that CNE2 cells were subcutaneously injected into the mice, after tumor formation, shERp44-exosomes or NC-exosomes were intratumorally injected every 2 days. We showed the representative pictures of NPC xenografts in nude mice. B. The histogram showed the weight of tumors in different groups (n = 5 per group). C. Western blot showed the expression of apoptosis markers in tumors when ERp44 was knocked down. D. Western blot showed the expression of apoptosis markers in tumors after ERp44 was knocked down with cisplatin treatment. E. Western blot showed the expression of apoptosis markers in tumors with shERp44-exosomes treatment. F: Western blot showed GSDME expression in tumors after ERp44 was knocked down. G: Western blot showed GSDME expression in tumors after ERp44 was knocked down with cisplatin treatment. H: Western blot showed GSDME expression in tumors with shERp44-exosomes treatments. * P < 0.05